Literature DB >> 17074682

p16INK4A (CDKN2A) gene deletion is a frequent genetic event in synovial sarcomas.

Manish M Subramaniam1, Rosa Noguera, Marta Piqueras, Samuel Navarro, Jose A López-Guerrero, Antonio Llombart-Bosch.   

Abstract

We assessed the frequency of genomic deletion of p16INK4A (CDKN2A) in synovial sarcomas (SSs) and its possible association with immunoexpression of p16 and cyclin D1 and the Ki-67 proliferation index using dual-color fluorescence in situ hybridization (FISH) on tissue microarray sections of 41 histologically and molecularly confirmed SSs. A heterozygous p16INK4A gene deletion was identified in 28 (74%) of 38 cases, with 25 (89%) of them showing abnormal p16 protein expression (20 negative and 5 heterogeneous). Of 25 cases, 19 (76%) exhibiting increased cyclin D1expression also demonstrated heterozygous p16INK4A deletion. No significant association was observed between p16INK4A deletion and Ki-67 proliferation index, tumor grade, or histologic subtype. Our results demonstrate that p16INK4A (CDKN2A) gene deletion is a frequent genetic event in SS.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17074682     DOI: 10.1309/E2AAY2XXN431WL81

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  3 in total

1.  Inhibition of cyclin-dependent kinase 4 as a potential therapeutic strategy for treatment of synovial sarcoma.

Authors:  Xiaoyang Li; Nicole A Seebacher; Cassandra Garbutt; Hangzhan Ma; Peng Gao; Tao Xiao; Francis J Hornicek; Zhenfeng Duan
Journal:  Cell Death Dis       Date:  2018-05-01       Impact factor: 8.469

2.  Targeting Cyclin-Dependent Kinases in Synovial Sarcoma: Palbociclib as a Potential Treatment for Synovial Sarcoma Patients.

Authors:  Myrella Vlenterie; Melissa H S Hillebrandt-Roeffen; Esther W M Schaars; Uta E Flucke; Emmy D G Fleuren; Anna C Navis; William P J Leenders; Yvonne M H Versleijen-Jonkers; Winette T A van der Graaf
Journal:  Ann Surg Oncol       Date:  2016-06-22       Impact factor: 5.344

Review 3.  Clinical Utility of CDK4/6 Inhibitors in Sarcoma: Successes and Future Challenges.

Authors:  Jocelyn Y Hsu; Nathan D Seligson; John L Hays; Wayne O Miles; James L Chen
Journal:  JCO Precis Oncol       Date:  2022-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.